

Data di nascita: 06/12/1988 | **Nazionalità:** Italiana | **Genere** Maschile | (+39) 3471979761 | giuseppe.auteri2@unibo.it |

Via Alessandro Bonci, 5, 40137, Bologna, Italia

● ESPERIENZA LAVORATIVA

15/03/2020 – ATTUALE

RICERCATORE UNIVERSITARIO

Lavoro come Libero Professionista presso il reparto di Ematologia del Policlinico S. Orsola di Bologna, per conto del Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

01/11/2019 – ATTUALE

DOTTORATO DI RICERCA – ALMA MATER STUDIORUM

Dottorato di ricerca, ciclo XXXV, "Oncologia, Ematologia e Patologia"

Attività assistenziale (diagnostico-terapeutica) rivolta ai pazienti affetti da patologie ematologiche presso l'UO di Ematologia del Policlinico S. Orsola di Bologna, in maniera specifica ai pazienti affetti da Neoplasie Mieloproliferative croniche e Piastrinopenia Immune.

Bologna, Italia

02/11/2015 – 31/10/2019

SPECIALIZZAZIONE IN EMATOLOGIA – MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITÀ E DELLA RICERCA

- management of the oncohematological patient
- management of the patient undergoing HSCT
- management of the patient with MPN
- management of the patient with ITP

<http://www.aosp.bo.it/> | Via Pietro Albertoni, 15, 40138, Bologna, Italia

01/08/2015 – 31/10/2015

MEDICO DI CONTINUITÀ ASSISTENZIALE – ASP ENNA

Attività di continuità assistenziale presso l'ASP di Enna, presso il presidio di Agira.

Enna, Italia

● ISTRUZIONE E FORMAZIONE

06/11/2019 – Bologna, Italia

SPECIALIZZAZIONE DI EMATOLOGIA – Università di Bologna

Specializzazione in Ematologia

FINAL EVALUATION: 110/110 + LODE

Livello 8 EQF

10/2014 – 06/2015 – Belpasso (CT), Italia

B1 CERTIFICATED ENGLISH COURSE – WES

12/02/2015 – Catania, Italia

ABILITAZIONE ALLA PROFESSIONE MEDICA – Università di Catania

FINAL EVALUATION: 110/110

Livello 7 EQF

09/09/2002 – 11/07/2007 – Paternò, Italia
MATURITÀ – Liceo Socio-psicopedagogico F. De Sanctis, Paternò

FINAL EVALUATION: 100/100

Livello 4 EQF

● **COMPETENZE LINGUISTICHE**

Lingua madre: ITALIANO

Altre lingue:

	COMPRENSIONE		ESPRESSIONE ORALE		SCRITTURA
	Ascolto	Lettura	Produzione orale	Interazione orale	
INGLESE	B2	C1	B2	B2	B2

Livelli: A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato

● **PUBBLICAZIONI**

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment

Hematol Oncol
<https://pubmed.ncbi.nlm.nih.gov/27510853/> – 2016

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34 + Cells

Mediators Inflamm
<https://pubmed.ncbi.nlm.nih.gov/30116149/> – 2018

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Leuk Res
<https://pubmed.ncbi.nlm.nih.gov/30321784/> – 2018

Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients

Br J Haematol
<https://pubmed.ncbi.nlm.nih.gov/30408157/> – 2019

Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis

Br J Haematol
<https://pubmed.ncbi.nlm.nih.gov/30450539/> – 2019

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Ann Hematol
<https://pubmed.ncbi.nlm.nih.gov/30515542/> – 2019

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study

Semin Hematol

<https://pubmed.ncbi.nlm.nih.gov/30502854/> - 2018

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs

Hematologica

<https://pubmed.ncbi.nlm.nih.gov/30846501/> - 2019

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

Hematol Oncol

<https://pubmed.ncbi.nlm.nih.gov/30985017/> - 2019

Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach

Hematol Oncol

<https://pubmed.ncbi.nlm.nih.gov/31359447/> - 2019

Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years

Thromb Res

<https://pubmed.ncbi.nlm.nih.gov/31783273/> - 2020

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Cancer

<https://pubmed.ncbi.nlm.nih.gov/31860137/> - 2020

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

Hematol Oncol

<https://pubmed.ncbi.nlm.nih.gov/32271957/> - 2020

Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms

Int J Mol Sci

<https://pubmed.ncbi.nlm.nih.gov/32403407/>

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis

Oncoimmunology

<https://pubmed.ncbi.nlm.nih.gov/32923146/> - 2020

Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series

Hematol Oncol

<https://pubmed.ncbi.nlm.nih.gov/32979286/> - 2020

Br J Hematol
<https://pubmed.ncbi.nlm.nih.gov/33222149/> - 2021

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

Br J Hematol
<https://pubmed.ncbi.nlm.nih.gov/33222197/> - 2021

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Blood Cancer J
<https://pubmed.ncbi.nlm.nih.gov/33414394/> - 2021

● **RETI E AFFILIAZIONI**

Appartenenza a gruppi / associazioni

- Iscrizione alla Società Italiana di Ematologia (ID iscrizione 4539) dal 23/04/2019
- VALDIG (VAscular Liver Disease Group), Università di Bologna, come consulente ematologo.

● **PROGETTI**

Clinical trials

- Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP). ClinicalTrials.gov Identifier: NCT02077192
- Ruxolitinib observational study in myelofibrosis treated patients in Italy. (ROMEI)
- Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2). ClinicalTrials.gov Identifier: NCT02038036
- Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) ClinicalTrials.gov Identifier: NCT02966353
- Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. ClinicalTrials.gov Identifier: NCT02426086
- Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With MF, Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2). ClinicalTrials.gov Identifier: NCT02101268
- A Study of LY2784544 in Participants With Myeloproliferative Neoplasms. ClinicalTrials.gov Identifier: NCT01594723
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (Low-PV). ClinicalTrials.gov Identifier: NCT03003325
- Eltrombopag in Second Line Adult Primary ITP. ClinicalTrials.gov Identifier: NCT02402998
- A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP (TAPER). ClinicalTrials.gov Identifier: NCT03524612
- A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With MF (MANIFEST). ClinicalTrials.gov Identifier: NCT02158858
- IMG-7289 in Patients With Myelofibrosis. ClinicalTrials.gov Identifier: NCT03136185
- An Efficacy and Safety Study of Fedratinib Compared to BAT in Subjects With DIPSS-intermediate or High-risk PMF, PPV-MF, PET-MF and Previously Treated With Ruxolitinib (FREEDOM2). ClinicalTrials.gov Identifier: NCT03952039
- Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/Chronic ITP. ClinicalTrials.gov Identifier: NCT04278924
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic MF Patients (MOMENTUM). ClinicalTrials.gov Identifier: NCT04173494
- A Phase 3 Study of Pacritinib in Patients With PMF, PPV-MF, or PET-MF (PACIFICA) ClinicalTrials.gov Identifier: NCT03165734
- Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change in Spleen Volume in Adult Participants With Myelofibrosis (TRANSFORM-1) ClinicalTrials.gov Identifier: NCT04472598
- Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) ClinicalTrials.gov Identifier: NCT04468984
- A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials. ClinicalTrials.gov Identifier: NCT04064060

- Porpora Trombocitopenica Idiopatica (ITP): Il punto sul trattamento nella pratica clinica.

● COMPETENZE PROFESSIONALI

Competenze professionali

A partire dal 2016 mi sono occupato del management dei pazienti affetti da Neoplasie Mieloproliferative Croniche Philadelphia negative (MPN) presso l'UO di Ematologia del Policlinico S.Orsola di Bologna, nello specifico:

- diagnosi delle MPN (Trombocitemia Essenziale, Policitemia Vera, Mielofibrosi)
- valutazione del rischio trombotico e quod vitam
- indicazione al trapianto allogenico di cellule staminali emopoietiche
- gestione della terapia
- raccolta ed elaborazione dati finalizzati alla ricerca scientifica
- partecipazione, come sub-investigatore, a trial clinici rivolti a pazienti affetti da MPN

● CERTIFICAZIONI

Certificazioni

- Cambridge English Entry Level Certificate in ESOL International (Entry 3) (Preliminary). 05 Aug 2015
- Basic Life Support - Defibrillation. Bologna 21 Oct 2016

● PRESENTAZIONI

27/09/2017

PRESENTAZIONI ORALI E LEZIONI

- Regional Meeting about ITP. Splenectomy and Rituximab pros and cons. Bologna 27 Sep 2017
- Myeloproliferative Neoplasms Philadelphia negative. Focus on Polycythemia Vera. Diagnostic criteria. Torino 23 Feb 2018
- Regional Meeting about Polycythemia Vera. Thromboses on PV and the role of ruxolitinib. Bologna 04 Jun 2018
- Regional Meeting about ITP. ITP in elderly patients. Bologna 26 Nov 2018.
- Scientific Meeting of the Seràgnoli Institute. Splanchnic Vein Thromboses and Myeloproliferative Neoplasms. Bologna 24 Jan 2019.
- Meeting with patients with ITP. Why participate in clinical trials. Milano 16 Mar 2019
- Immune Thrombocytopenia: state of art and experience. ITP and surgery. Bologna 27 Jun 2019
- Regional meeting about PV. Resistance criteria to hydroxyurea. Bologna 08 Jul 2019
- Regional Meeting about ITP. About ITP patient and thrombosis. Bologna 18 Nov 2019
- Diagnosi differenziale delle piastrinosi. Lezione a specializzandi di Medicina Interna 2020-2021
- Trombosi Splanchniche e Neoplasie Mieloproliferative Croniche. Lezione a specializzandi di Medicina Interna 2020-2021
- Diagnosi differenziale delle piastrinopenie. Lezione a specializzandi di Medicina Interna 2020-2021
- Terapie di combinazione, pazienti refrattari e nuove terapie dell'ITP. Meeting regionale sull'ITP. Webinar. 18 Nov 2020
- Nuovi paradigmi terapeutici della Policitemia Vera. Meeting scientifici di Istituto. 09 Jan 2021

● CONFERENCES AND MEETING

Conferences and meeting

- Advanced ITP Discussion project. Bari 27-28 Nov 2015
- ReTHINK Global Investigator Meeting. Barcelona 15 Apr 2016
- New Drugs in Hematology. Bologna 9 May 2016
- SIE Congress. Rome 15-18 Oct 2017
- News about American Society of Haematology meeting. Milan 08-10 Mar 2018
- New Drugs in Hematology. Bologna 1-3 Oct 2018
- ARES National Investigator Meeting. Rome 12 Nov 2018
- News about American Society of Haematology meeting. Bologna 14-16 Feb 2018
- SIE Congress. Rome 07-09 Oct 2019
- Advance Discussion in ITP. Sorrento 15-16 Nov 2019

● **CORSI**

Corsi

- 4th National Course of Interactive Hematology. Catania 6 - 7 Feb 2015
- Interactive Lesson of Hematology. Catania 2 Oct 2015
- GITMO Educational Course. New Drugs and transplant. Udine 21-22 Jan 2016
- Hematological Romagna's Saturdays. Faenza 14 May 2016
- How communicate scientific knowing. Bologna 28 Oct 2016
- Talking about Myelofibrosis and MPNs. Bologna 21 Nov 2016
- Romagna's haematologic project 2017
- Meet the Experts on MPNs: from the bench to the bedside. 25-27 May 2017
- Romagna's haematologic project 2018
- Masterclass on Myeloproliferative Neoplasms. Florence 03-04 May 2018
- MDS: diagnosis, prognosis and therapy. Bologna 06 Oct 2018
- Romagna's haematologic project 2019